Tianjin Second People's Hospital Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2019
NCT04028323
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Tianjin Second People's Hospital

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fibrosis (Phase 3)

Hemorrhage (Phase 4)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis B (Phase 3)

Hepatitis C (Phase 3)

Liver Cirrhosis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 8